PineDev
1 min read
The Future of the Aging Eye
AnnMarie Hipsley, the Founder and CEO of Ace Vision Group (AVG), a Delaware, USA- based company developing innovative therapeutics for age-related ocular dysfunctions, talks to The Ophthalmologist about her background and work with AVG, and the company’s short- and long-term goals.
She explains how the Group has utilized artificial intelligence and virtual reality platforms to develop the Next Gen VisioLite laser, paints a broad picture of the current gaps in available treatment models for age-related eye diseases, such as presbyopia, and goes into detail about how Laser Scleral Microporation Therapeutic Laser Rejuvenation (LSM) eye therapy sits within the future landscape of treatments for these disorders.
Explore More Articles
Improvement in Accommodation and Dynamic Range of Focus After Laser Scleral Microporation: A Potential Treatment for Presbyopia
Purpose: To examine the ocular changes in accommodation, wavefront aberrations, and dynamic range of focus (DROF) after laser scleral microporation (LSM) for treating presbyopia.
read moreRobert Ang Discusses LSM by Ace Vision
Robert T. Ang, refractive surgeon at the Asian Eye Institute in the Philippines, talks to The Ophthalmologist about the ways Laser Scleral Microporation (LSM) therapy offered by Ace Vision Group comes to benefit him and his patients. He discusses the therapy’s mechanism of action, what the procedure involves, and the unique value offered by LSM. …
read moreNew-generation software further improves precision of laser scleral microporation
VIENNA — In this Healio Video Perspective from the ESCRS meeting, Luca Gualdi, MD, speaks about the latest advances in laser scleral microporation. Laser scleral microporation (LSM, Ace Vision Group) is a treatment that restores accommodation in presbyopic patients by uncross-linking the scleral tissue that becomes stiff with age. It does so by performing arrays of micropores in …
read more